6.4 Hyperbaric Oxygen Therapy, Biophysical Modalities, and Revascularization Indications

Hyperbaric Oxygen Therapy: Physical Laws and Physiological Mechanisms

Hyperbaric Oxygen Therapy (HBOT) is an advanced systemic medical intervention in which a patient breathes 100% medical-grade oxygen intermittently while inside a pressurized treatment chamber at pressures greater than sea-level atmospheric pressure—typically between 2.0 and 2.5 atmospheres absolute (ATA). In diabetic limb salvage, HBOT is utilized to overcome severe tissue hypoxia, combat refractory deep infections, and stimulate tissue regeneration in recalcitrant wounds.

The Biophysical Principles: Henry's Law

The primary physical foundation governing HBOT is Henry's Law, which states that the mass of a gas dissolved in a given volume of liquid is directly proportional to the partial pressure of that gas in equilibrium with the liquid.

+-------------------------------------------------------------------------+
|               HENRY'S LAW AND PLASMA OXYGEN TRANSPORT                   |
+------------------------------------+------------------------------------+
| NORMOBARIC ROOM AIR (1.0 ATA, 21% O2)| HYPERBARIC OXYGEN (2.5 ATA, 100% O2) |
+------------------------------------+------------------------------------+
| - Alveolar pO2: ~100 mmHg          | - Alveolar pO2: ~1,800–2,000 mmHg  |
| - Arterial PaO2: ~90–100 mmHg      | - Arterial PaO2: > 1,500–1,800 mmHg|
| - Hemoglobin: ~97% saturated       | - Hemoglobin: 100% saturated       |
| - Dissolved in Plasma:             | - Dissolved in Plasma:             |
|     0.3 mL O2 per 100 mL blood     |     6.0 mL O2 per 100 mL blood     |
|     (Negligible contribution)      |     (Meets resting tissue demand!) |
+------------------------------------+------------------------------------+

Under normal physiological resting conditions at sea level (1.0 ATA breathing room air):

• Nearly all oxygen delivered to tissues is bound reversibly to hemoglobin within red blood cells.
• The volume of oxygen dissolved directly in blood plasma is a negligible 0.3 mL of O2 per 100 mL of blood (0.3 volume percent).

When a patient is placed inside a hyperbaric chamber at 2.5 ATA breathing 100% oxygen:

• Arterial oxygen partial pressure ($PaO_2$) skyrockets from ~100 mmHg to well over 1,500 to 2,000 mmHg.
• The volume of oxygen dissolved physically in blood plasma surges to approximately 6.0 mL of O2 per 100 mL of blood—a 15- to 20-fold increase.
• Crucially, normal resting human tissue extracts approximately 5.0 to 6.0 mL of oxygen per 100 mL of perfused blood. Under 2.5 ATA of pure oxygen, dissolved plasma oxygen alone satisfies total cellular resting metabolic oxygen demand, completely bypassing the need for hemoglobin-erythrocyte oxygen transport.

Oxygen Diffusion Gradient and Microvascular Penetration

In patients with diabetic neuroischemic ulcers, microvascular disease, arteriolosclerosis, and extensive localized interstitial edema create a formidable diffusion barrier between patent capillaries and hypoxic parenchymal cells. According to Fick's Law of Diffusion, the rate of gas transfer across a tissue barrier is directly proportional to the concentration gradient. The massive plasma partial pressure generated during HBOT creates an exceptionally steep diffusion gradient, quadrupling the effective radial oxygen diffusion distance from capillary walls into surrounding ischemic and edematous tissue beds.

Cellular and Molecular Mechanisms of HBOT

+-------------------------------------------------------------------------+
|                 BIOCHEMICAL CASCADE TRIGGERED BY HBOT                   |
+-------------------------------------------------------------------------+
| Hyperoxic Exposure (2.0–2.5 ATA) -> Hyperoxygenated Plasma              |
|        |                                                                |
|        v                                                                |
| Fuels Neutrophil Oxidative Burst (NADPH Oxidase -> ROS Generation)      |
| Direct killing of anaerobes & microaerophiles (MRSA / Clostridia)       |
|        |                                                                |
|        v                                                                |
| Transient Hyperoxia/Relative Hypoxia Cycle -> Stabilizes HIF-1alpha     |
|        |                                                                |
|        v                                                                |
| Massive Upregulation of VEGF, bFGF & Endothelial Progenitor Mobilization|
| (eNOS activation releases CD34+ stem cells from bone marrow)            |
|        |                                                                |
|        v                                                                |
| Accelerated Neo-Angiogenesis, Fibroblast Proliferation & Collagen Cross-linking|
+-------------------------------------------------------------------------+

1. Restoration of Neutrophil Oxidative Burst: Hypoxic tissues (tissue $pO_2$ < 30 mmHg) severely impair polymorphonuclear neutrophil (PMN) function. Leukocytes require molecular oxygen as a direct substrate for the enzyme NADPH oxidase, which generates reactive oxygen species (ROS)—superoxide radicals ($O_2^{\bullet-}$), hydrogen peroxide ($H_2O_2$), and hypochlorous acid ($HOCl$)—essential for phagocytic killing of bacteria. HBOT elevates tissue oxygen tensions well above the 30 to 40 mmHg critical threshold required for full oxidative burst capacity.
2. Direct Antimicrobial Lethality: Free active oxygen radicals exert direct bacteriostatic and bactericidal effects against obligate anaerobes (e.g., Clostridium perfringens, Bacteroides fragilis) by overwhelming their deficient antioxidant enzyme defenses (superoxide dismutase, catalase). It also suppresses alpha-toxin production.
3. Neo-Angiogenesis via HIF-1α and Growth Factor Signaling: HBOT sessions create cyclic peaks of hyperoxia followed by relative hypoxia. This cycling stabilizes Hypoxia-Inducible Factor 1-alpha (HIF-1α), triggering sustained transcription and synthesis of Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF). This drives capillary sprouting, endothelial cell proliferation, and capillary loop formation in previously avascular tissue beds.
4. Bone Marrow Stem Cell Mobilization: HBOT stimulates endothelial nitric oxide synthase (eNOS) activity within the bone marrow, triggering the rapid mobilization of CD34+ endothelial progenitor cells (EPCs) into peripheral circulation. These circulating progenitor cells home directly to ischemic diabetic wound beds to participate in vasculogenesis and tissue remodeling.
5. Fibroblast Proliferation and Collagen Synthesis: Fibroblasts require molecular oxygen as an essential cofactor for prolyl hydroxylase and lysyl hydroxylase, the enzymes responsible for hydroxylating proline and lysine residues during collagen biosynthesis. Hydroxylation is mandatory for collagen triple-helix stabilization and tensile cross-linking.

---

Clinical Indications, Protocols, and Contraindications of HBOT

Current IWGDF guidance conditionally considers systemic HBOT as an adjunct for selected neuro-ischemic or ischemic diabetic foot ulcers when good standard care has failed and local resources and patient factors support treatment. Wagner grade or a fixed 30-day rule alone is not sufficient. Revascularization, infection source control, wound care, and offloading remain central; HBOT does not overcome an uncorrected large-vessel obstruction.

Approved UHMS Indication in Diabetic Foot Disease

The Undersea and Hyperbaric Medical Society (UHMS) establishes strict clinical evidence criteria for hyperbaric therapy. In diabetic lower extremity management, HBOT is indicated for:

• Wagner Grade 3, 4, or 5 Diabetic Foot Wounds: Wounds penetrating deeply into tendon, joint capsule, or bone (e.g., deep plantar abscess, joint sepsis, or osteomyelitis) that have failed at least 30 consecutive days of standard comprehensive multidisciplinary wound care (adequate debridement, offloading, moist dressing care, and appropriate systemic antimicrobial therapy).
• Chronic Refractory Diabetic Foot Osteomyelitis: Deep bone infections that have failed standard surgical resection or prolonged culture-directed antibiotic regimens.
• Compromised Surgical Flaps or Failing Amputations: Compromised transmetatarsal amputation flaps or failing reconstructive soft tissue envelopes showing marginal tissue ischemia.
• Note: HBOT is not indicated for superficial Wagner Grade 1 or 2 ulcers without deep structural infection.

Clinical Treatment Protocols and Chamber Types

• Monoplace Chamber: A single-occupant acrylic cylinder pressurized entirely with 100% medical-grade oxygen. The patient breathes ambient chamber oxygen without requiring a mask or hood.
• Multiplace Chamber: A large multi-occupant steel pressure vessel pressurized with ambient medical air. Patients breathe 100% oxygen through a tight-fitting silicone face mask, mouthpiece, or head tent, with built-in air-break intervals to diminish oxygen toxicity risk.
• Standard Treatment Regimen: Pressurized to 2.0 to 2.5 ATA for 90 to 120 minutes of pure oxygen breathing per session, administered once daily, 5 days per week. A standard clinical course requires 30 to 40 sessions (dives), with formal objective clinical re-evaluation performed after 20 and 30 treatments.

Safety Contraindications

+-------------------------------------------------------------------------+
|                   CONTRAINDICATIONS TO HYPERBARIC OXYGEN                |
+------------------------------------+------------------------------------+
| ABSOLUTE CONTRAINDICATION          | KEY PHARMACOLOGICAL TOXICITIES     |
+------------------------------------+------------------------------------+
| - Untreated pneumothorax is absolute | - Selected medications require specialist review |
| - Pressure equalization limitations | - Prior bleomycin exposure raises pulmonary concern |
| - Acute instability may delay care | - Review doxorubicin, cisplatin, disulfiram and others |
+------------------------------------+------------------------------------+

• The Absolute Contraindication: Untreated Pneumothorax:
  • During hyperbaric pressurization, gas volume decreases in accordance with Boyle's Law ($P_1V_1 = P_2V_2$). If a patient with an untreated pneumothorax enters the chamber, gas in the pleural space compresses. During chamber decompression (as ambient pressure decreases), the trapped intrapleural gas expands rapidly. Without a functional chest tube, this trapped gas generates a rapid tension pneumothorax, causing mediastinal shift, vena cava compression, and immediate fatal cardiovascular collapse.
  • Mandatory Action: An untreated pneumothorax must be converted to an open drainage system via tube thoracostomy (chest tube) prior to hyperbaric chamber entry.
• Pharmacological Contraindications:
  • Doxorubicin (Adriamycin): Hyperbaric oxygen amplifies doxorubicin-mediated free radical generation in cardiac myocytes, inducing acute, fatal cardiotoxicity and heart failure. Must be discontinued at least 48 to 72 hours prior to HBOT.
  • Bleomycin: Prior exposure raises concern for oxygen-related pulmonary toxicity and requires specialist risk assessment; it is not equivalent to the universal absolute contraindication of an untreated pneumothorax.
  • Cisplatin: Concurrent HBOT impairs renal tubular healing, markedly exacerbating nephrotoxicity and peripheral neurotoxicity.
  • Disulfiram (Antabuse): Inhibits endogenous superoxide dismutase (SOD), stripping host tissues of their primary defense against oxygen-free radicals and dramatically lowering the threshold for central nervous system oxygen toxicity.
  • Mafenide Acetate (Sulfamylon): Topical carbonic anhydrase inhibitor that promotes systemic metabolic acidosis, worsening central hypercapnic vasodilation.
• Relative Contraindications:
  • Severe chronic obstructive pulmonary disease (COPD) with chronic $CO_2$ retention (hyperoxia eliminates the hypoxic respiratory drive, inducing acute respiratory arrest).
  • Uncontrolled seizure disorders (oxygen toxicity lowers the central seizure threshold).
  • High untreated fever (fever accelerates cerebral metabolic rate, precipitating central nervous system oxygen toxicity seizures [Paul Bert effect]).
  • Eustachian tube dysfunction (inability to equalize middle ear pressure during pressurization produces middle ear barotrauma; requires prophylactic tympanostomy tube placement).
  • Severe claustrophobia (managed with anxiolytics).

---

Pre-Therapy Assessment: Transcutaneous Oximetry (TcPO2)

Transcutaneous Oximetry (TcPO2) is the primary noninvasive diagnostic tool used to assess localized periwound microvascular perfusion, determine baseline hypoxia, and predict whether a diabetic foot ulcer will clinically respond to HBOT.

Testing Methodology

Clark-type polarographic oxygen sensors are adhered to intact periwound skin surrounding the ulcer (and a reference control site on the subclavicular chest). The sensor heating element warms the underlying skin to 43°C to 44°C. Heating induces maximal local capillary vasodilation, liquefies the crystalline lipid structure of the stratum corneum, and facilitates the uninhibited diffusion of dissolved oxygen from papillary capillary loops through the epidermis to the platinum cathode, measuring local skin oxygen tension in mmHg.

Diagnostic Interpretation and the Oxygen Challenge

+-------------------------------------------------------------------------+
|               TcPO2 DIAGNOSTIC AND PROGNOSTIC INTERPRETATION           |
+-----------------------+-------------------------------------------------+
| > 50–60 mmHg          | Normal cutaneous perfusion; adequate for healing|
| 30–50 mmHg            | Mild-to-moderate ischemia; delayed healing      |
| < 30 mmHg (Baseline)  | Critical tissue hypoxia; spontaneous healing    |
|                       | impossible without intervention                 |
+-----------------------+-------------------------------------------------+
| THE OXYGEN CHALLENGE: Inhale 100% O2 under normobaric/hyperbaric load   |
+-----------------------+-------------------------------------------------+
| TcPO2 rises > 200 mmHg| EXCELLENT HBOT RESPONDER (> 80% healing probability)
| (or increases > 100)  | Confirms microvascular reserve and capillary flux|
+-----------------------+-------------------------------------------------+
| TcPO2 remains < 50–100| HBOT FAILURE PREDICTOR; Profound macrovascular  |
| mmHg                  | arterial occlusion; URGENT REVASCULARIZATION   |
+-----------------------+-------------------------------------------------+

• Baseline Room Air Values:
  • In a healthy foot, TcPO2 values range from 50 to 70 mmHg.
  • A baseline room air TcPO2 < 30 mmHg indicates severe localized tissue hypoxia and critical limb ischemia. Spontaneous healing without specialized intervention is statistically negligible.
• The Oxygen Challenge Test:
  • The patient breathes 100% normobaric oxygen via a high-flow non-rebreather mask (or inside the hyperbaric chamber during an initial test profile).
  • Response to oxygen: A substantial TcPO₂ rise shows oxygen-delivery reserve and may help with selection, but no oxygen-challenge value guarantees healing or isolates all vascular limitations.
  • Poor response: A persistently low reading strengthens concern about perfusion and prompts vascular reassessment. Technical and systemic causes are also reviewed; the result does not by itself mandate a single procedure.

---

Emerging Biophysical Modalities in Wound Healing

Mechanistic interest does not establish clinical benefit. Current IWGDF guidance does not recommend electrical stimulation or other listed physical therapies as routine interventions solely to improve diabetic foot-ulcer healing. If discussed, label them investigational or unsupported rather than standard care.

1. Low-Frequency Non-Contact Ultrasound (LFNCUS / MIST Therapy):
   • Technology: Delivers continuous low-frequency ultrasound waves (typically 40 kHz) transmitted through a fine, atomized, continuous mist of sterile saline without direct probe contact with the wound bed.
   • Biophysical Action: Operates via acoustic cavitation and acoustic microstreaming. Cavitational energy fragments and destabilizes bacterial biofilms, increases cell membrane permeability, disrupts bacterial cell walls, and stimulates local vasodilation and protein synthesis, significantly reducing bioburden while accelerating granulation.
2. Continuous Topical Oxygen Therapy (TOT):
   • Technology: A lightweight, wearable, battery-powered electrochemical oxygen generator that extracts oxygen from ambient air and delivers continuous, pure (98–99%), humidified oxygen at low flow rates (typically 3 to 15 mL/hour) directly to the wound surface under an occlusive dressing 24 hours a day, 7 days a week.
   • Clinical Utility: Unlike systemic HBOT, TOT diffuses oxygen topically into the superficial wound bed (up to a depth of 1 to 2 mm) without requiring chamber access or carrying risks of barotrauma and oxygen toxicity. Indicated for outpatient management of stalled, superficial-to-partial thickness DFUs.
3. Electrical Stimulation (ESTIM):
   • Technology: Application of low-voltage pulsed current (LVPC) directly across the wound bed using surface electrodes.
   • Biophysical Action: Re-establishes the physiological "current of injury" disrupted by chronic ulceration. Induces electrotaxis, guiding the directional migration of negatively charged granulocytes, macrophages, and fibroblasts into the wound core, stimulating microvascular blood flow and collagen synthesis.

---

Critical Indications and Decision Pathways for Vascular Revascularization

Advanced biotherapies, cellular products, and hyperbaric oxygen cannot compensate for unaddressed macrovascular ischemia. Clinicians must recognize the absolute diagnostic triggers mandating urgent vascular referral:

+-------------------------------------------------------------------------+
|               VASCULAR REVASCULARIZATION DECISION TRIGGERS              |
+-------------------------------------------------------------------------+
| - Absolute Toe Systolic Pressure < 30 mmHg                              |
| - Ankle Systolic Pressure < 50 mmHg (or ABI < 0.40–0.50)                |
| - Periwound TcPO2 < 30 mmHg with failed Oxygen Challenge (< 50 mmHg)    |
| - Flat, monophasic, non-pulsatile Continuous-Wave Doppler waveforms     |
| - Non-healing DFU after 4 weeks with documented PAD                     |
+-------------------------------------------------------------------------+
|                                 |                                       |
|                                 v                                       |
|       URGENT VASCULAR SURGERY / INTERVENTIONAL REFERRAL                 |
|                                 |                                       |
|        +------------------------+------------------------+              |
|        v                                                 v              |
| ENDOVASCULAR REVASCULARIZATION            OPEN SURGICAL BYPASS          |
| (Balloon Angioplasty / Stenting)          (Autologous Saphenous Vein)   |
| - Preferred first-line in frail patients  - Preferred for long-segment  |
| - Focal stenoses; tibial vessels           multilevel tibial occlusions |
+-------------------------------------------------------------------------+

Revascularization Modalities

• Endovascular Intervention: Balloon angioplasty, cutting balloons, drug-coated balloons, and bare-metal or drug-eluting stents. It is minimally invasive, performed under local anesthesia with conscious sedation, and represents the first-line revascularization approach for elderly, medically frail diabetic patients with focal infrapopliteal or femoropopliteal stenoses.
• Open Surgical Bypass: Autologous saphenous vein bypass grafting (e.g., femoral-to-anterior tibial or dorsalis pedis bypass). It provides superior long-term primary patency for extensive, calcified, long-segment chronic total occlusions (CTOs) of the tibial and peroneal vessels in suitable surgical candidates.
• Clinical Sequencing Rule: Arterial revascularization must always precede aggressive debridement of dry ischemic digits and must be confirmed prior to applying high-cost CTPs or advanced biophysical modalities.

---

Modality Comparison: Advanced Biophysical and Revascularization Therapies